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Objective:  To prospectively  evaluate  individual  functional  MRI  metrics  for  the  early  prediction  of patho-
logical  complete  response  (pCR)  to neo-adjuvant  chemotherapy  (NAC)  in breast  cancer.
Materials  and  methods:  Thirty-two  women  (median  age  52  years;  range  32–71  years)  with biopsy
proven  breast  cancer  due  to  receive  neo-adjuvant  anthracycline  and/or  taxane-based  chemotherapy  were
prospectively  recruited  following  local  research  ethics  committee  approval  and written  informed  con-
sent. Breast  MRI  was  performed  prior  to  and  after  two  cycles  of  NAC  and  pCR  was  assessed  after  surgery.
The enhancement  fraction  (EF),  tumour  volume,  initial  area  under  the  gadolinium  curve (IAUGC),  phar-
macokinetic  parameters  (Ktrans, kep and  ve), the  apparent  diffusion  coefﬁcient  (ADC)  and  R2*  values,  along
with  the  percentage  change  in  these  parameters  after  two  cycles  were  evaluated  according  to pCR  status
using an  independent  samples  t-test.  The  area  under  the  receiver  operating  characteristics  curve  (AUC)
was calculated  for each  parameter.  Linear  discriminant  analysis  (LDA)  determined  the  most  important
parameter  in  predicting  pCR.
Results:  A  reduction  in  the  EF  (−41% ± 38%)  and  tumour  volume  (−80%  ± 25%)  after  2 cycles  of NAC  were
signiﬁcantly  greater  in those  achieving  pCR  (p =  0.025,  p =  0.011  respectively).  A  reduction  in  the  EF of
7%  after  2 cycles  of  NAC  identiﬁed  those  more  likely  to achieve  pCR  (AUC  0.76). AUC  changes  in other
parameters  were  tumour  volume  (0.77),  IAUGC  (0.64),  Ktrans (0.60),  kep (0.68),  ve (0.58), ADC  (0.69)  and
R2*  (0.41).
Conclusion:  In a multi-parametric  MRI  model,  the decrease  in a non-model  based  vascular  parameter  the
enhancement  fraction  as well  as  the  tumour  volume  are  the  most  important  early  predictors  of pCR  in
breast  cancer.
. Introduction
Neo-adjuvant chemotherapy (NAC) is increasingly being offered
o women with breast cancer in order to down-stage the tumour
nd facilitate breast conserving surgery. The vast majority of
omen taking NAC will have a clinical response, [1] and a propor-
ion will go on to achieve pathological complete response (pCR) on
nal surgical histology, more likely if tumours are triple negative
r HER2-positive in subtype [2]. Achieving pCR is highly desirable
s it confers a notable survival advantage, being associated with
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improved overall and improved disease free survival [3]. However,
NAC can have signiﬁcant treatment-related physical and psycho-
logical co-morbidity, and early identiﬁcation of a subset of patients
who would be more likely to likely to achieve beneﬁt compared
to those in whom response is poor might tailor management that
would avoid the administration of potentially toxic and ineffective
therapy.
Imaging the in situ tumour at an early time point allows eval-
uation of quantitative functional MRI  metrics that can potentially
be used to predict which patients are more likely to achieve pCR.
These parameters interrogate the local microcirculation, cellular
environment, chemical composition and inﬂuence of hypoxia in
parallel [4] and their combination potentially improves the assess-
ment of tumour response [5]. Changes in functional MRI  metrics
are reported within a tumour before reduction in standard RECIST
measurements [6]; a reduction in the pharmacokinetic parame-
ters Ktrans and kep after 2 cycles has been shown to be predictive
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f response [7,8], along with a rise in the apparent diffusion coefﬁ-
ient (ADC) from diffusion-weighted (DW)- imaging [9] and a rise
n R2* values from intrinsic susceptibility weighted (ISW)-MR [10].
ecent experience from a large multicentre collaboration, the I-
PY trial (ACRIN 6657) reported that volumetric measurement of
umour response early in treatment was the most useful parameter
n predicting response because pharmacokinetic analysis may  be
oo complicated to use in every day clinical practice [11]. Although
he utility of simpler, non-model based vascular parameters, such
s the enhancement fraction (EF) has shown to provide robust and
eproducible measurements [12], its use in predicting response
arly during a course of NAC in breast cancer has not been explored.
herefore the aim of this study was to prospectively evaluate the
erformance of non-model based versus model based MRI  in the
arly prediction of pCR to NAC in breast cancer.
. Materials and methods
.1. Subjects and treatment
This single centre prospective trial was Health Insurance
ortability and Accountability Act (HIPAA) compliant. Following
esearch ethics committee approval, patient written informed con-
ent was obtained from participants. Between December 2010 and
une 2013, 32 patients with histologically proven invasive breast
ancer underwent breast MRI  prior to commencing and again after
 cycles of NAC. Inclusion criteria were women aged 18–90 years
ho were not pregnant or breast feeding and with no contra-
ndication to MRI. After completion of NAC patients underwent
urgery which was either wide local excision or mastectomy. A
tandard NAC regimen was administered, which at our institution
outinely involved 8 cycles of treatment: 4 cycles of anthracycline-
ased epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2)
ollowed by 4 cycles of taxane based therapy with paclitaxel
175 mg/m2) (n = 17). Patients whose tumours failed to respond
based on an imaging assessment of non-reduction in size or pro-
ression of the tumour), were switched after 2 cycles of epirubicin
nd cyclophosphamide to paclitaxel (n = 1), docetaxel (75 mg/m2)
n = 1) or carboplatin and paclitaxel (n = 2) to try and achieve a
esponse. Patients whose tumours underwent a complete clin-
cal and radiological response after 4 cycles of epirubicin and
yclophosphamide were referred for surgery at that stage (n = 1).
rastuzumab (Herceptin) was added to the taxane component
f neo-adjuvant chemotherapy in HER2 positive tumours (n = 7).
aclitaxel was given alone as ﬁrst-line therapy for 6 cycles (n = 1),
ollowed by exemestane (25 mg)  (n = 1), epirubicin and cyclophos-
hamide for 4 cycles (n = 1) and in combination with carboplatin
n = 1), dependent on the individual patient’s chemotherapeutic
istory.
Pathological response was evaluated on ﬁnal surgical histology
ith patients classiﬁed as a responder if they had achieved pCR (no
nvasive and no in situ residual disease in the breast or nodes) [3]
r near pCR (where there may  be non-measurable isolated micro-
copic foci of residual invasive or in situ disease. Non-responders
ad measurable residual invasive and in situ disease [13].
.2. MR  imaging acquisition and analysis
MR  Imaging was performed on a 3.0T Philips Achieva MRI
canner (Best, Netherlands) using a dedicated 7 channel
ilateral breast coil. A diagnostic T2-weighted (T2W) axial bilateral
equence was performed initially for lesion localisation followed
y a DW-sequence, an ISW-sequence and a DCE-sequence over
he tumour-containing breast. Intravenous contrast injection of
.2 ml/kg of gadoterate meglumine (n = 20) or gadopentate dimeg-f Radiology 85 (2016) 837–842
lumine (n = 12) with a 20 ml  saline ﬂush was  given before the
DCE-sequence. Subsequent pharmacokinetic analysis took into
account the different relaxivities of the contrast media. A ﬁnal
post-contrast high-resolution T1-weighed (T1W) sequence was
performed. Scanning parameters are shown in Table 1.
Regions of Interest (ROIs) were drawn off-line, manually,
freehand and slice-by-slice as whole tumour ROIs on an early sub-
tracted post contrast (120s) sagittal DCE-MRI image using software,
MRIW (Institute of Cancer Research, London) [14]. ROI placement
was guided by the anatomical MRI  images with recent mammog-
raphy and ultrasound images used as further aides for reference,
and drawn to exclude artifacts, blood vessels and surrounding fat.
Whole tumour ROI’s were chosen as endorsed by an international
consensus panel on DCE-MRI methodology for use in clinical trials
[15]. DCE-MRI images were acquired from T1W and proton density-
weighed sequences with two  ﬂip angles of 16◦ and 3◦ respectively
for subsequent conversion of the DCE-MRI signal intensity to con-
trast agent concentrations. Pre-contrast T1 values for the adipose
breast tissue were estimated on MRIW.  The T1 values in fatty tissues
were lower than expected values of ∼360 ms  [16], necessitating a
software correction in the ﬂip angle. This was performed by reduc-
ing the ﬂip angles by a factor of approximately 0.5, (to 1.5◦ and 8◦
instead of 3◦ and 16◦ respectively) to take into account the variation
in B1 inhomogeneity.
Concentration-time curves were ﬁtted on a pixel-by-pixel basis
using an extended Tofts pharmacokinetic model to calculate quan-
titative perfusion parameters [17]. A population-averaged arterial
input function was used [18]. Non-enhancing pixels were excluded
in this part of the analysis to prevent biasing of results. Quan-
titative kinetic parameters Ktrans (min−1), kep (min−1) and ve (%)
were recorded. Parameters independent of mathematical mod-
elling were also obtained including the enhancement fraction
(EF) (%) = (total number of enhancing pixels/total number of pix-
els), tumour volume (mm3) = (total number of pixels per slice x
reconstructed voxel size) and initial area under the gadolinium
curve (IAUGC (mmol  L−1 sec−1). The enhancement threshold was
deﬁned as a statistically signiﬁcant increase in signal in each pixel
where every point on the uptake curve between 30 and 90 s after
onset were twice the standard deviation above the mean pre-
enhancement value. ADC (mm2/s) and R2* (sec−1) values were also
recorded pixel-by-pixel using Adept software (Institute of Cancer
Research, London). ADC values were computed from a mono-
exponential ﬁtting of signal intensity for all 4 b values. R2* maps
were computed using echo times between 4.6 ms  and 59.81 ms,  as
signals at higher echo times were within the noise ﬂoor. The choice
of equal slice thickness (3 mm)  and sagittal orientation for the DW-,
T2* and DCE-sequences resulted in good alignment of the ROIs, with
only minor adjustment required on the ADC maps to compensate
for geometric distortion. For all variables except the enhancement
fraction and tumour volume, median values were obtained from
the pixel-by-pixel data for each patient and the percentage change
after 2 cycles calculated for each parameter.
2.3. Statistical analysis
Statistical analysis was  performed using SPSS for Windows ver-
sion 18, (SPSS, Chicago, IL, USA). The difference in overall mean
values for all parameters (EF, tumour volume, IAUGC, Ktrans, kep,
ve, ADC and R2) before and after 2 cycles of chemotherapy was
evaluated using a paired t-test. The percentage change in mean
parameter values between baseline and 2 cycles of NAC was
calculated and an independent samples t-test used to evaluate the
difference between those who  achieved pCR/near pCR and those
who did not. A p value <0.05 was used to indicate a signiﬁcant
difference.
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Table  1
3.0T MRI  sequence parameters.
Parameter DWI  T2* DCE
Technique Single shot EPI Gradient echo FFE 3D gradient echo FFE
Imaging plane Sagittal Sagittal Sagittal
Fat  suppression SPAIR + SSGR N/A Subtracted
Echo  Time (TE) 67 ms  2.3 ms 2.3 ms
Repetition Time (TR) 3771 ms  1400 ms  4.5 ms
Phase encoding Foot-head Foot-head Foot-head
First  echo N/A 4.6 ms N/A
Echo  spacing N/A 6.9 ms N/A
Number of echoes N/A 12 N/A
Acquisition time 3:42 min  3:31 min 8:28 min
FOV  180 mm 180 mm 180 mm
Acquisition voxel size 2 × 2 × 3 mm 1.2 × 1.2 × 3 mm 2.4 × 2.4 × 3 mm
Reconstructed voxel size 1 × 1 × 3 mm 1 × 1 × 3 mm 1 × 1 × 3 mm
Slice  thickness/gap 3 mm/no gap 3 mm/no gap 3 mm/no gap
Parallel imaging No SENSE No SENSE No SENSE
Acquisition matrix size 92 × 89 mm 148 × 150 mm 76 × 75 mm
Bandwidth 17 Hz 866.3 Hz 2692.5 Hz
b  values 0, 100, 700, 1150 s/mm2 N/A N/A
Slices  17 17 17
Flip  angle 90◦ 18◦ 16◦
Inversion delay 60 ms  N/A N/A
Dynamic scans N/A N/A 200
Dynamic scan time N/A N/A 2.5 s
EPI—echoplanar imaging.
FFE—fast ﬁeld echo.
N/A—not applicable.
Table 2
Percentage parameter differences after 2 cycles of neo-adjuvant chemotherapy.
Parameter % change Responders (n = 13) % change Non-responders (n = 19) P value
Enhancement Fraction −41 ± 38 −12 ± 25 0.025
Tumour volume −80 ± 25 −53 ± 32 0.011
IAUGC −48 ± 40 −32 ± 31 0.245
Ktrans −43 ± 42 −25 ± 37 0.210
kep −57 ± 42 −31 ± 29 0.07
14 ± 29 0.256
13 ± 20 0.230
16 ± 26 0.663
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Table 3
The linear discriminant analysis structure matrix. Variables are ordered by absolute
size of correlation within function.
Parameter Function
EF 0.628
Tumour volume 0.618
kep 0.491
ADC 0.339
IAUGC 0.300
R2* −0.115ve −7 ± 58 
ADC  −4 ± 44 
R2*  21 ± 42 
Receiver operating characteristic (ROC) curve analysis was  per-
ormed; the area under the ROC curve (AUC) was  estimated to
etermine sensitivity and speciﬁcity for the percentage change
n each metric in or differentiating pCR from no pCR. Linear dis-
riminant analysis (LDA) was performed to determine the most
mportant predictive metric for determining pCR. The minimum
cceptable ratio of patients: independent variables for LDA of 5:1
as adhered to [19].
. Results
Thirteen patients had a pCR/near pCR at surgery (median age
2 years, range 32–71 years) and were classiﬁed as responders.
9 patients did not (median age 51 years, range 36–63 years)
nd were classiﬁed as non-responders. There was  no signiﬁcant
ifference in the age between responders and non-responders
p = 0.496). There was a signiﬁcant difference in the mean tumour
ize before (50 mm ± 20 mm)  and after 2 cycles (17 mm ± 15 mm)
p < 0.0001) in the responders; a smaller but still signiﬁcant differ-
nce in the mean tumour size before (45 mm ± 16 mm)  and after
 cycles (38 mm ± 15 mm)  was also seen in the non-responders
p = 0.018).
There were signiﬁcantly greater decreases in the EF and tumour
olume in responders (enhancement fraction −41% ± 38%, tumour
olume −80% ± 25%) compared to non-responders (enhancement
raction −12% ± 25%; tumour volume −53% ± 32%) after 2 cycles of
hemotherapy (p = 0.025 and p = 0.011 respectively) (Table 2).LDA performed using the percentage change in 6 metrics (EF,
tumour volume, IAUGC, kep, ADC and R2*) indicated that the
parameters EF and tumour volume were primarily contributing to
the identiﬁcation of response, while all other parameters (IAUGC,
kep, ADC and R2*) were non-contributory (Table 3). kep was the
pharmacokinetic parameter included in the LDA as it was  the mod-
elled metric that showed the most signiﬁcant difference between
responders and non-responders after 2 cycles.
After LDA, ROC analysis indicated that a decrease in the EF of
7% indicated pCR with a sensitivity of 63% and speciﬁcity of 77%
(AUC = 0.76). By comparison a decrease in the tumour volume of
71% was needed to show a sensitivity of 74% and speciﬁcity of 77%
(AUC = 0.77). The area under the ROC curves for each parameter
with the optimal cut-off values and the corresponding sensitivity
and speciﬁcity at that cut-off are shown in Table 4 with ROC curves
840 E.A. O’Flynn et al. / European Journal of Radiology 85 (2016) 837–842
Fig. 1. ROC curves for respond
Table 4
ROC curve analysis showing sensitivity and speciﬁcity for each parameter after 2
cycles at the optimal cut-off for distinguishing responders from non-responders.
Parameter Cut-off AUC Sensitivity (%) Speciﬁcity (%)
EF ↓7% 0.757 63.2 76.9
Tumour volume ↓71% 0.773 71.4 76.9
IAUGC ↓47% 0.644 73.7 61.5
Ktrans ↓39% 0.599 63.2 53.8
kep ↓37% 0.676 63.2 69.2
v ↑11% 0.575 57.9 53.8
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ADC ↓0.4% 0.688 78.9 69.2
R2* ↑5% 0.407 63.2 30.8
llustrated in Fig. 1. Multi-parametric images from a responder
efore treatment and after 2 cycles are shown in Fig. 2.
. Discussion
In assessing response to NAC, the EF was the best discriminator
f pCR with a relatively small percentage decrease of 7% after 2
ycles yielding a sensitivity of 63% and speciﬁcity of 77% (AUC 0.76).
n comparison, the other discriminator, tumour volume required
 much greater percentage decrease (71%) to yield an equivalent
peciﬁcity of 77% but had an improved sensitivity of 74% (AUC 0.77).
herefore a small reduction in the EF early in treatment can be
sed to identify those more likely to achieve pCR because of its
peciﬁcity. An index combining the EF and tumour volume may
ell therefore provide the most accurate predictor of pCR.
The EF is a relatively simple semi-quantitative variable that is
 newly described measure of proportional tumour enhancement
erived from DCE-MRI [20]. It is a percentage measure the number
f early enhancing pixels within the whole tumour. It can provide
dditional information as a non-modelled alternative to pharma-
okinetic metrics and informs on whole tumour enhancement.
tandard time-signal intensity curves by comparison, generally use
elective small ROIs, often reporting the “worst” or most malignanters and non-responders.
curve obtained. The EF is highly reproducible with a coefﬁcient
of variation of 8.6% in a cohort of advanced solid tumours [12]
and is therefore more reliable than pharmacokinetic parameters.
The EF provides vascular information that might be overlooked on
standard DCE-MRI and potentially presents an easier non-model
based parameter of response. Further work is required to determine
robustness of the EF in the breast and standardise the enhancement
threshold which in this study was deﬁned a signiﬁcant increase
in post-contrast signal twice the standard deviation above the
mean pre-enhancement signal at 30–90 s on the uptake curve and
designed to detect pixels that persistently enhanced above the
baseline noise [21]. The importance of the rate constant, kep in this
model should also be emphasised as it was  the only other variable
to show a signiﬁcantly greater reduction in responders compared
to non-responders. The kep describes the wash-out rate of contrast
and the importance of the kep in the LDA structure matrix therefore
stresses the value of standard time-signal intensity curves when
assessing response to NAC [22].
The tumour volume after 2 cycles is an alternative response
biomarker, but in this cohort a greater reduction was needed to
determine pCR. ROC analysis showed that the sensitivity of the
reduction in tumour volume was  higher than that for the EF with
identical speciﬁcity. The I-SPY trial (ACRIN6657) found that the
greatest advantage was obtained from breast MRI  when using volu-
metric assessment of response early in treatment [11]. Single centre
cohort studies have also shown a signiﬁcant decrease in tumour
volume when monitoring response at an early time point [23–26]
and this cohort corroborates these ﬁndings. Despite this, LDA indi-
cated that the EF was  the most important metric in discriminating
pCR over and above tumour volume, afﬁrming that it is a good
predictor variable from a multi-parametric acquisition.
ADC measurements from this multi-parametric model showed
no impact in differentiating responders from non-responders. ADC
values in fact demonstrated a small fall in those achieving pCR and
a rise in the non-responders. The majority of complete responders
E.A. O’Flynn et al. / European Journal of Radiology 85 (2016) 837–842 841
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ize  after 2 cycles of neoadjuvant chemotherapy with almost no enhancement visib
ere either triple negative or HER2 positive in tumour subtype,
oth of which are recognised to have a higher ADC than lumi-
al subtypes [27,28]. These subtypes have a higher pCR rate and
requently disappear altogether in responders leading to a fall in
he overall ADC value because of the return of fat within a treated
umour [2]. While many studies have demonstrated that respon-
ers have a lower pre-treatment ADC [26,29,30], Richard et al.
howed that pre-treatment ADC was signiﬁcantly higher in those
ho went on to achieve pCR [31]. The results from this study concur
nd indicate the inﬂuence of tumour subtype in achieving pCR, and
hat it likely surpasses the inﬂuence of imaging parameters. The R2*
alues from this cohort showed the least impact in discriminating
arly response, showing an increase of 21% in responders and 16%
n non-responders. The only previous study reporting R2* values
n the breast showed an increase of 15% in responders and 6.5%
n non-responders after 2 cycles [10] likely due to a reduction in
etabolism of the tumour. When evaluated in a multi-parametric
odel the R2* was the least valuable parameter, being overshad-
wed by the vascular metrics.owing Ktrans, IAUGC, ADC and R2*. This tumour has shown a signiﬁcant decrease in
Finally, even though most women  received a standard anthra-
cycline/taxane NAC regimen, a minority of patients in this cohort
had variable chemotherapeutic regimens. This is practised at our
institution to allow personalisation of therapies offered and takes
into account any chemotherapy the patient may  have received
before. At completion these frequently surmounted to the same
drugs being administered, albeit in different orders due to previ-
ous history, tolerance and chemotherapeutic toxicity. In order to
develop reliable and practical imaging biomarkers of response in
everyday clinical practice, allowances will need to be made for this,
supporting our use of slightly variable chemotherapeutic regimens
in this study.
5. ConclusionIn conclusion, the EF, a non-model based vascular parameter,
in conjunction with tumour volume, should be considered for the
early prediction of response in breast cancer.
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